Interventional technology developer AngioDynamics has posted financial results for the first quarter of 2020 (end-August 31).
The company had first-quarter sales of $66 million, an increase of 3.3% compared with $63.9 million in the same period last year. Sales for its Oncology division were $14 million, an increase of 20.9% from $11.6 million a year ago, while sales for its Vascular Interventions and Therapies division were $28.9 million, an increase of 1.1% compared with $28.6 million a year ago.
The firm's net loss for the period was $1.3 million, compared with a net loss of $469,000 during the same period last year.
In other AngioDynamics news, the company has acquired Eximo Medical and its 355-nm-wavelength laser atherectomy technology for $46 million, with up to $20 million further payment contingent on particular technical and revenue milestones, it said. The technology has received clearance from the U.S. Food and Drug Administration (FDA) for treating peripheral artery disease.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
